Vanda Pharmaceuticals (VNDA) News Today $5.00 -0.10 (-1.96%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.comStockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Sunday. They issued a "hold" rating on the stock.November 17 at 3:03 AM | marketbeat.comVanda Pharmaceuticals Announces Participation at November 2024 Investor ConferencesNovember 12, 2024 | prnewswire.comBML Capital Management LLC Cuts Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)BML Capital Management LLC decreased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 42.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 228,500 sharesNovember 12, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Vigil Neuroscience Inc (VIGL)November 9, 2024 | markets.businessinsider.comStockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)November 9, 2024 | americanbankingnews.comVanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.comStockNews.com started coverage on shares of Vanda Pharmaceuticals in a research report on Saturday. They issued a "hold" rating for the company.November 9, 2024 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comVanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ...November 7, 2024 | finance.yahoo.comVanda Pharmaceuticals narrows 2024 revenue view to $190M-$210M from $180M-$210MNovember 7, 2024 | markets.businessinsider.comVanda Pharmaceuticals Reports Strong Q3 2024 GrowthNovember 7, 2024 | markets.businessinsider.comVanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comVanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c)November 6, 2024 | tipranks.comVanda Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | prnewswire.comQ3 Earnings Estimate for VNDA Issued By HC WainwrightVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - HC Wainwright issued their Q3 2024 EPS estimates for Vanda Pharmaceuticals in a report released on Thursday, October 31st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings of ($0.16) per shaNovember 4, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDANovember 2, 2024 | prnewswire.comOver 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: AnalystNovember 1, 2024 | benzinga.comResearch Analysts Offer Predictions for VNDA FY2024 EarningsVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Analysts at HC Wainwright issued their FY2024 EPS estimates for shares of Vanda Pharmaceuticals in a report released on Thursday, October 31st. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earningsNovember 1, 2024 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Vanda Pharmaceuticals (VNDA) with Buy RecommendationNovember 1, 2024 | msn.comVanda started at buy by H.C. Wainwright, negative enterprise value citedOctober 31, 2024 | msn.comVanda Pharmaceuticals initiated with a Buy at H.C. WainwrightOctober 31, 2024 | markets.businessinsider.comVanda Pharmaceuticals (VNDA) to Release Earnings on WednesdayVanda Pharmaceuticals (NASDAQ:VNDA) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at HC WainwrightHC Wainwright started coverage on Vanda Pharmaceuticals in a report on Thursday. They set a "buy" rating and a $18.00 price objective for the company.October 31, 2024 | marketbeat.comVanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024October 30, 2024 | prnewswire.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 17.1% in OctoberVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,980,000 shares, an increase of 17.1% from the September 30th total of 3,400,000 shares. Based on an average daily trading volume, of 596,200 shares, the days-to-cover ratio is currently 6.7 days. Currently, 7.2% of the company's shares are sold short.October 28, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDAOctober 25, 2024 | prnewswire.comBiotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & MoreOctober 18, 2024 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDAOctober 17, 2024 | prnewswire.comCycle Pharmaceuticals reaffirms proposal to acquire Vanda PharmaceuticalsOctober 15, 2024 | finance.yahoo.comVanda Pharma soars as Cycle Pharma reiterates $8/share offer (update)October 14, 2024 | msn.comVanda Shares Climb on Reiterated Cycle Acquisition OfferOctober 14, 2024 | marketwatch.comCycle Pharma Is Said to Stand By $488 Million Offer for VandaOctober 14, 2024 | bloomberg.comVanda Pharmaceuticals rejects Cycle Pharma's second takeover offerOctober 14, 2024 | investing.comVanda Pharmaceuticals Rejects Deal Proposal From Cycle GroupOctober 14, 2024 | marketwatch.comVanda Pharma Gets Second Unsolicited Acquisition Offer From Cycle GroupOctober 14, 2024 | markets.businessinsider.comVanda Pharma soars as Cycle Pharma reiterates $8/share offerOctober 14, 2024 | msn.comVanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.October 14, 2024 | prnewswire.comCycle Pharma maintains takeover offer for Vanda PharmaceuticalsOctober 14, 2024 | reuters.comCycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per ShareOctober 14, 2024 | businesswire.comProfit Investment Management LLC Sells 241,502 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Profit Investment Management LLC lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 42.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 329,822 shares of the biopharmaceutical company's stock after selling 241,502October 11, 2024 | marketbeat.comSquarepoint Ops LLC Sells 156,573 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Squarepoint Ops LLC decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 66.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 79,030 shares of the biopharmaceutical company's stock after selling 156,573 shares dOctober 10, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDAOctober 9, 2024 | prnewswire.comVanda Pharma (NASDAQ:VNDA) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comVanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.comStockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Tuesday. They issued a "hold" rating on the stock.October 8, 2024 | marketbeat.comDimensional Fund Advisors LP Raises Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Dimensional Fund Advisors LP lifted its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 17.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,013,807 shares of the biopharmaceutical company's stock after acquiring anOctober 7, 2024 | marketbeat.comSei Investments Co. Sells 123,694 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Sei Investments Co. decreased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 23.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 395,157 shares of tOctober 5, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDAOctober 3, 2024 | prnewswire.comNantahala Capital Management LLC Increases Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Nantahala Capital Management LLC boosted its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 57.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,593,516 shares of the biopharmaceutical company's stock afteOctober 1, 2024 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.comStockNews.com began coverage on shares of Vanda Pharmaceuticals in a research report on Sunday. They issued a "hold" rating for the company.September 22, 2024 | marketbeat.comVanda Pharmaceuticals Inc.: FDA Declines to Approve Vanda's Marketing Application for Tradipitant in GastroparesisSeptember 21, 2024 | finanznachrichten.deRenaissance Technologies LLC Cuts Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Renaissance Technologies LLC lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,114,125 shares of the biophaSeptember 21, 2024 | marketbeat.com Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern… Follow this link here and enter your email address to sign up… VNDA Media Mentions By Week VNDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼1.000.56▲Average Medical News Sentiment VNDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼44▲VNDA Articles Average Week Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gossamer Bio News Today AnaptysBio News Today OPKO Health News Today Ironwood Pharmaceuticals News Today Emergent BioSolutions News Today Sangamo Therapeutics News Today XOMA News Today Codexis News Today Lexicon Pharmaceuticals News Today Rigel Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
